Inventor · disambiguated record
Fajun Nan
Also filed as: NAN FAJUN
26 granted patents·9 pending applications·394 citations·filing 2000–2023
95Inventor score
Files withSHANGHAI INST MATERIA MEDICA CAS12NAN FAJUN8SHANGHAI INST MATERIA MEDICA5UNIV GEORGETOWN3HOFFMANN LA ROCHE2
Top patents by PatentIndex Score
35 records- 0198US6528499B1Ligands for metabotropic glutamate receptors and inhibitors of NAALADaseUNIV GEORGETOWN·Filed 2000·Granted Mar 4, 2003·154 cites·39 claims
- 0297US7381745B2Ligands for metabotropic glutamate receptors and inhibitors of NAALADaseUNIV GEORGETOWN·Filed 2003·Granted Jun 3, 2008·60 cites·4 claims
- 0395US6479470B1Ligands for metabotropic glutamate receptors and inhibitors of NAALAdaseUNIV GEORGETOWN·Filed 2000·Granted Nov 12, 2002·97 cites·67 claims
- 0491US8455510B2Rapamycin carbonic ester analogues, pharmaceutical compositions, preparations and uses thereofNAN FAJUN·Filed 2009·Granted Jun 4, 2013·47 cites·8 claims
- 0585US8609721B2Ligands for metabotropic glutamate receptors and inhibitors of NAALADaseKOZIKOWSKI ALAN P·Filed 2008·Granted Dec 17, 2013·4 cites·9 claims
- 0683US7741348B2Bisheterocycle tandem compounds useful as antiviral agents, the uses thereof and the compositions comprising such compoundsSHANGHAI INST MATERIA MEDICA·Filed 2006·Granted Jun 22, 2010·12 cites·4 claims
- 0778US9353048B2Compound as KCNQ potassium channel agonist, preparation method therefor and use thereofSHANGHAI INST MATERIA MEDICA·Filed 2012·Granted May 31, 2016·6 cites·4 claims
- 0876US8653115B2Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agentsNAN FAJUN·Filed 2007·Granted Feb 18, 2014·5 cites·5 claims
- 0972US9216962B2Thiazole compounds, methods for preparation and use thereofNAN FAJUN·Filed 2012·Granted Dec 22, 2015·3 cites·13 claims
- 1072US8778973B2Alkene oxindole derivativesHOFFMANN LA ROCHE·Filed 2013·Granted Jul 15, 2014·2 cites·31 claims
- 1167US8247549B2Method for preparing 4-(6-amino-purin-9-YL)-2(S)-hydroxy-butyric acid methyl esterNAN FAJUN·Filed 2008·Granted Aug 21, 2012·2 cites·11 claims
- 1262US7838682B2Glucagon-like peptide-1 receptor agonists, the preparation and the use of the sameSHANGHAI INST MATERIA MEDICA·Filed 2003·Granted Nov 23, 2010·2 cites·2 claims
- 1362US2025144127A1Long-chain compound and use thereofBURGEON THERAPEUTICS CO LTD·Filed 2022·Application pending·0 cites
- 1459US11192916B2Pentacyclic triterpene compound and preparation method therefor, and pharmaceutical composition and use thereofSHANGHAI INST MATERIA MEDICA CAS·Filed 2018·Granted Dec 7, 2021·0 cites·4 claims
- 1559US2024351966A1Class of alkylphenol compounds and preparation method thereforSHANGHAI INST MATERIA MEDICA CAS·Filed 2022·Application pending·0 cites
- 1657US2025122148A1High-selectivity kcnq4 potassium channel agonist, preparation method therefor and use thereofSHANGHAI INST MATERIA MEDICA CAS·Filed 2023·Application pending·0 cites
- 1756US2025011272A1Long-chain compound that acts on acly, preparation method therefor and use thereofSHANGHAIINSTITUTE OF MATERIA MEDICA CHINESE ACAD OF SCIENCES·Filed 2022·Application pending·0 cites
- 1854US2014288127A1Novel Alkene Oxindole DerivativesHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 1951US2024342201A1Asymmetric gpr84 antagonist and use thereofSHANGHAI INST OF MATERIA METERIA MEDICA CHINESE ACADEMY OF SCIENCES·Filed 2022·Application pending·0 cites
- 2048US8470763B2Alpha-amino-N-substituted amides, pharmaceutical composition containing them and uses thereofNAN FAJUN·Filed 2008·Granted Jun 25, 2013·0 cites·13 claims
- 2148US8183383B2Protein tyrosine phosphatase 1B inhibitor, preparation methods and uses thereofNAN FAJUN·Filed 2008·Granted May 22, 2012·0 cites·13 claims
- 2245US10316008B2KCNQ potassium channel agonist, and preparation method therefor and use thereofSHANGHAI INST MATERIA MEDICA CAS·Filed 2018·Granted Jun 11, 2019·0 cites·17 claims
- 2344US8039492B2Substituted cyclic compound, its preparation process and its medical useSHANGHAI INST MATERIA MEDICA·Filed 2006·Granted Oct 18, 2011·0 cites·8 claims
- 2443US10766889B2Aryl-2,2′-tandem bisthiazole compound and preparation method and use thereofSHANGHAI INST MATERIA MEDICA CAS·Filed 2017·Granted Sep 8, 2020·0 cites·19 claims
- 2542US7683073B2Isoquinoline-1,3,4-trione compounds, the synthetic method and the use thereofSHANGHAI INST MATERIA MEDICA·Filed 2005·Granted Mar 23, 2010·0 cites·9 claims
- 2641US11098071B2GPR84 receptor antagonist and use thereofSHANGHAI INST MATERIA MEDICA CAS·Filed 2018·Granted Aug 24, 2021·0 cites·11 claims
- 2738US8426606B22′,2-bisthiazole non-nucleoside compounds, preparation methods, pharmaceutical compositions and uses as hepatitis virus inhibitors thereofNAN FAJUN·Filed 2011·Granted Apr 23, 2013·0 cites·18 claims
- 2837US10414713B2Fatty acid compound, preparation method therefor and use thereforSHANGHAI INST MATERIA MEDICA CAS·Filed 2017·Granted Sep 17, 2019·0 cites·9 claims
- 2937US10077245B2KCNQ potassium channel agonists, method of preparation and method of use thereofSHANGHAI INST MATERIA MEDICA CAS·Filed 2015·Granted Sep 18, 2018·0 cites·15 claims
- 3036US2005113420A1Methionine aminopeptidase inhibitorFiled 2003·Application pending·0 cites
- 3135US10278962B2Tricyclic analogues, preparation method and uses thereofSHANGHAI INST MATERIA MEDICA CAS·Filed 2016·Granted May 7, 2019·0 cites·6 claims
- 3235US2018237399A1Compounds having agonistic effect against gpr84, preparation method for compounds and use of compoundsSHANGHAI INST MATERIA MEDICA CAS·Filed 2016·Application pending·0 cites
- 3331US10196389B2One class of pyrazolone compounds and use thereofSHANGHAI INST MATERIA MEDICA CAS·Filed 2015·Granted Feb 5, 2019·0 cites·15 claims
- 3430US2012264793A1Pharmaceutical Use of 2',2-Bis-Thiazole Non-Nucleoside Compounds as Hepatitis C Virus InhibitorNAN FAJUN·Filed 2010·Application pending·0 cites
- 3529US9643941B22,2′-tandem dithiazole compound, preparation method therefor, and use thereofSHANGHAI INST MATERIA MEDICA CAS·Filed 2015·Granted May 9, 2017·0 cites·9 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →